Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.58 |
| ▸ | HINT1 | P49773 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26198 | 1.00 | ADORA2A (0.58) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL2345479 | 0.99 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL2345484 | 0.99 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL31107536 | 0.99 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL5963089 | 0.99 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL24968582 | 0.99 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL5963095 | 0.99 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL27659 | 0.97 | ADORA2A (0.58) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL27658 | 0.97 | ADORA2A (0.58) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL27351 | 0.94 | HINT1 (0.59) | ADORA2AADORA2BHINT1HPGDNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048826-A1 | Oligonucleotides containing 2'-0-modified purines | ISIS PHARMACEUTICALS, INC. | 2004-03-11 | — | — | US | claimed |
| US-20250188477-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE HAVING RNAi ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| WO-2025110249-A1 | COMPOSITION FOR NUCLEOTIDE SEQUENCE EDITING, AND NUCLEOTIDE SEQUENCE EDITING METHOD USING SAME | 国立大学法人 広島大学 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025063238-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF PHOSPHOLAMBAN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025063239-A1 | SIRNA CAPABLE OF SUPPRESSING EXPRESSION OF α-SYNUCLEIN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| CN-115976028-B | Glycogen disease type Ia therapeutic agent | 第一三共株式会社 | 2025-03-25 | — | — | CN | disclosed |
| CN-114080238-B | Nucleic acid medicine for inhibiting mRNA production of myostatin gene | 神户天然物化学株式会社 | 2025-02-07 | — | — | CN | disclosed |
| EP-4495240-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2 | Daiichi Sankyo Company, Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| CN-119326905-A | GalNAc-oligonucleotide conjugate for delivery to liver and preparation method thereof | 第一三共株式会社 | 2025-01-21 | — | — | CN | disclosed |
| US-5672472-A | REPEATED ENZYME-FREE SYNTHESIS OF INCREASINGLY SIMPLIFIED SETS OF OLIGONUCLEOTIDES WHILE DETERMINING WHICH SEQUENCE HAS HIGHEST TARGET ACTIVITY | ISIS PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5646265-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMCEUTICALS, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5506351-A | Process for the preparation of 2'-O-alkyl guanosine and related compounds | ISIS PHARMACEUTICALS (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0651759-A4 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. | ISIS PHARMACEUTICALS INC (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0673435-A4 | — | — | 1995-10-25 | — | — | EP | disclosed |
| EP-0673435-A1 | SYNTHETIC UNRANDOMIZATION OF OLIGOMER FRAGMENTS | ISIS PHARMACEUTICALS, INC. (US) | 1995-09-27 | — | — | EP | disclosed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994021825-A1 | COMBINATORIAL OLIGOMER IMMUNOABSORBANT SCREENING ASSAY FOR TRANSCRIPTION FACTORS AND OTHER BIOMOLECULE BINDING | ISIS PHARMACEUTICALS, INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
| WO-1993004204-A1 | SYNTHETIC UNRANDOMIZATION OF OLIGOMER FRAGMENTS | ISIS PHARMACEUTICALS, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | TFRC, FOLR2, FTH1 | ADORA2A 3422/4885ADORA2B 3863/4885HINT1 3720/4885 |
| US-20040048826-A1 | Oligonucleotides containing 2'-0-modified purines | NSUN2, RNMT, HNRNPL | ADORA2A 132/4885ADORA2B 301/4885HINT1 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.